TAMOXIFEN THERAPY AND RISK OF COLORECTAL CANCER
他莫昔芬治疗与结直肠癌的风险
基本信息
- 批准号:2433759
- 负责人:
- 金额:$ 4.51万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1997
- 资助国家:美国
- 起止时间:1997-07-01 至 1999-06-30
- 项目状态:已结题
- 来源:
- 关键词:breast neoplasm /cancer diagnosis breast neoplasms cancer registry /resource cancer risk chemoprevention clinical research colorectal neoplasms drug adverse effect drug screening /evaluation human subject human therapy evaluation neoplasm /cancer chemotherapy neoplasm /cancer epidemiology outcomes research questionnaires tamoxifen
项目摘要
A recent report from three Scandinavian clinical trials evaluating
tamoxifen therapy among breast cancer patients has raised concern
that tamoxifen therapy could increase the risk of a subsequent
colorectal malignancy. We propose to test the hypothesis that
tamoxifen use among breast cancer patients is associated with an
elevated risk of second primary colorectal cancer in a
population-based study.
The proposed study is a nested case-control investigation of new
primary colon and retal cancers among women with a prior
diagnosis of brest cancer. Women diagnosed with Stage I, II, or III
breast cancer between January 1, 1978 and December 31, 1992 will
be identified from the population-based Cancer Surveillance
System (CSS) of western Washington. All women in the study
cohort who are subsequently diagnosed with new primary colon or
retal cancer as their secondary primary cancer at least six months
following the unilateral diagnosis and before December 31, 1994
will be study cases (total, n=161). For each case, we will identify
at least two controls from the study cohort matched on the
following characteristics of the case at the time of unilateral
diagnosis: calendar year, age (in 5 year age groups), stage of
disease (I,II, or III) (n=361).
Tamoxifen therapy and other study information, will be obtained
by abstracting hospital medical records of cases and controls and
through a self-administered questionnaire sent to physicians who
were involved in each patients' care. Analyses will be conducted
to compare the relative risk of colorectal cancer in relation to the
duration and recency of tamoxifen use.
The success of tamoxifen as a breast cancer therapy, coupled with
the minimal short-term effects, has initiated interest in using
tamoxifen prophylactically in primary prevention of breast cancer.
It is reasonable to expect that long-term adverse effects will be
accepted and tolerated by most breast cancer patients, since
tamoxifen has demonstrated efficacy for this potentially
life-threatening disease. Such effects may not be acceptable to
healthy women, including those at higher than average risk for
breast cancer. It is important to document all beneficial and
adverse health effects associated with tamoxifen treatment so that
an informed decision can be made with respect to the prophylactic
use of the drug.
最近一份来自三个斯堪的纳维亚临床试验的报告,
他莫昔芬治疗乳腺癌引起了关注
他莫昔芬治疗可能会增加
结直肠恶性肿瘤 我们建议检验这个假设,
乳腺癌患者使用他莫昔芬与
第二原发性结直肠癌的风险增加,
基于人口的研究。
这项研究是一项巢式病例对照研究,
原发性结肠癌和直肠癌的女性,
乳腺癌的诊断 诊断为I、II或III期的女性
1978年1月1日至1992年12月31日之间的乳腺癌将
从基于人群的癌症监测中识别
华盛顿西部的CSS系统。 研究中的所有女性
随后被诊断为新的原发性结肠或
视网膜癌作为继发原发癌至少6个月
1994年12月31日之前,
将是研究病例(总数,n=161)。 对于每种情况,我们将确定
来自研究队列的至少两个对照组在
以下是案件单方面时的特点
诊断:日历年,年龄(5岁年龄组),阶段
疾病(I、II或III)(n=361)。
将获得他莫昔芬治疗和其他研究信息
通过提取病例和对照的医院医疗记录,
通过向医生发送自填式问卷,
参与到每个病人的护理中。 将进行分析
比较结直肠癌的相对风险与
他莫昔芬使用的持续时间和最近度。
他莫昔芬作为乳腺癌治疗的成功,加上
最小的短期影响,引发了使用的兴趣
他莫昔芬在乳腺癌一级预防中的应用
有理由预计,长期不利影响将是
大多数乳腺癌患者都接受并耐受,因为
他莫昔芬已经证明了对这种潜在的
危及生命的疾病。 这种影响可能是不可接受的,
健康女性,包括那些高于平均风险的女性,
乳腺癌 重要的是要记录所有有益的,
与他莫昔芬治疗相关的不良健康影响,
可以做出关于预防药物的知情决定
药物的使用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Linda S Cook其他文献
Databases and models : new tools for management
数据库和模型:新的管理工具
- DOI:
- 发表时间:
2021 - 期刊:
- 影响因子:0
- 作者:
Eileen O Dareng;Simon G. Coetzee;J. Tyrer;Pei;Will L. Rosenow;Stephanie S. Chen;B. Davis;F. Dezem;Ji;Robbin Nameki;A. L. Reyes;Katja K.H. Aben;H. Anton;N. Antonenkova;G. Aravantinos;E. Bandera;L. B. Beane Freeman;M. W. Beckmann;A. Beeghly;Javier Benítez;Marcus Q Bernardini;L. Bjørge;A. Black;N. Bogdanova;Kelly L Bolton;J. D. Brenton;A. Budziłowska;R. Butzow;H. Cai;Ian Campbell;R. Cannioto;J. Chang;S. Chanock;Kexin Chen;G. Chenevix;Y. Chiew;Linda S Cook;Anna deFazio;J. Dennis;J. Doherty;T. Dörk;A. du Bois;M. Dürst;Diana M Eccles;G. Ene;Peter A. Fasching;James M. Flanagan;R. Fortner;F. Fostira;A. Gentry;Graham G. Giles;Marc T Goodman;J. Gronwald;C. Haiman;N. Håkansson;F. Heitz;Michelle A. Hildebrandt;E. Høgdall;C. K. Høgdall;R. Huang;A. Jensen;Michael E Jones;D. Kang;B. Karlan;A. Karnezis;Linda E. Kelemen;Catherine J. Kennedy;Elza K. Khusnutdinova;L. Kiemeney;S. K. Kjaer;J. Kupryjańczyk;Marilyne Labrie;D. Lambrechts;M. Larson;Nhu D Le;J. Lester;Lian Li;J. Lubiński;M. Lush;Jeffrey R Marks;K. Matsuo;T. May;John R. McLaughlin;I. McNeish;Usha Menon;Stacey Missmer;F. Modugno;M. Moffitt;Alvaro N Monteiro;K. Moysich;Steven A Narod;T. Nguyen;Kunle Odunsi;Håkan Olsson;N. Onland;Sue K Park;T. Pejovic;J. Permuth;A. Piskorz;D. Prokofyeva;Marjorie J. Riggan;Harvey A. Risch;C. Rodríguez‐Antona;M. Rossing;Dale P. Sandler;V. W. Setiawan;Kang Shan;Honglin Song;M. Southey;Helen Steed;R. Sutphen;Anthony J Swerdlow;Soo;K. Terry;P. Thompson;Liv Cecilie Vestrheim Thomsen;Linda Titus;B. Trabert;R. Travis;Shelley S. Tworoger;Elena Valen;E. Van Nieuwenhuysen;D. V. Edwards;R. Vierkant;P. Webb;Clarice R. Weinberg;Rayna Matsuno Weise;Nicolas Wentzensen;Emily White;S. Winham;Alicja Wolk;Y. Woo;Anna H Wu;Li Yan;D. Yannoukakos;Nur Zeinomar;W. Zheng;A. Ziogas;A. Berchuck;E. Goode;David G Huntsman;C. Pearce;S. Ramus;T. A. Sellers;M. Freedman;K. Lawrenson;J. Schildkraut;D. Hazelett;Jasmine T Plummer;Siddhartha P Kar;Michelle R. Jones;Paul D. P. Pharoah;S. Gayther - 通讯作者:
S. Gayther
Early menopause and hormone therapy as determinants for lung health outcomes: a secondary analysis using the PLCO trial.
早期绝经和激素治疗作为肺部健康结果的决定因素:使用 PLCO 试验的二次分析。
- DOI:
- 发表时间:
2024 - 期刊:
- 影响因子:10
- 作者:
Xiaochun Gai;Yue Feng;Tessa M Flores;Huining Kang;Hui Yu;Kimberly K Leslie;Yiliang Zhu;Jennifer A Doherty;Yan Guo;Steven A Belinsky;Linda S Cook;Shuguang Leng - 通讯作者:
Shuguang Leng
Linda S Cook的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Linda S Cook', 18)}}的其他基金
A Population Based Study of Ketorolac and Ovarian Cancer Survival
酮咯酸与卵巢癌生存的人群研究
- 批准号:
10457136 - 财政年份:2020
- 资助金额:
$ 4.51万 - 项目类别:
A Population Based Study of Ketorolac and Ovarian Cancer Survival
酮咯酸与卵巢癌生存的人群研究
- 批准号:
9885784 - 财政年份:2020
- 资助金额:
$ 4.51万 - 项目类别:
A Population Based Study of Ketorolac and Ovarian Cancer Survival
酮咯酸与卵巢癌生存的人群研究
- 批准号:
10543498 - 财政年份:2020
- 资助金额:
$ 4.51万 - 项目类别:
Mitochondrial DNA and Ovarian Cancer Risk and Survival
线粒体 DNA 与卵巢癌风险和生存
- 批准号:
8660048 - 财政年份:2012
- 资助金额:
$ 4.51万 - 项目类别:
Mitochondrial DNA and Ovarian Cancer Risk and Survival
线粒体 DNA 与卵巢癌风险和生存
- 批准号:
8296141 - 财政年份:2012
- 资助金额:
$ 4.51万 - 项目类别:
Mitochondrial DNA and Ovarian Cancer Risk and Survival
线粒体 DNA 与卵巢癌风险和生存
- 批准号:
9054818 - 财政年份:2012
- 资助金额:
$ 4.51万 - 项目类别:
Mitochondrial DNA and Ovarian Cancer Risk and Survival
线粒体 DNA 与卵巢癌风险和生存
- 批准号:
8517630 - 财政年份:2012
- 资助金额:
$ 4.51万 - 项目类别:
Uterine cancer survival disparities, Hispanic ethnicity, and comorbidities.
子宫癌生存差异、西班牙裔和合并症。
- 批准号:
7781057 - 财政年份:2009
- 资助金额:
$ 4.51万 - 项目类别:
Uterine cancer survival disparities, Hispanic ethnicity, and comorbidities.
子宫癌生存差异、西班牙裔和合并症。
- 批准号:
7941753 - 财政年份:2009
- 资助金额:
$ 4.51万 - 项目类别:
TAMOXIFEN THERAPY AND RISK OF COLORECTAL CANCER
他莫昔芬治疗与结直肠癌的风险
- 批准号:
2748891 - 财政年份:1997
- 资助金额:
$ 4.51万 - 项目类别:
相似海外基金
Pathology of Breast Neoplasms determined by MRS
MRS 测定乳腺肿瘤的病理学
- 批准号:
nhmrc : 950215 - 财政年份:1995
- 资助金额:
$ 4.51万 - 项目类别:
NHMRC Project Grants